Bone Biologics, headquartered in Burlington, Massachusetts, focuses on developing bone graft substitutes for spinal fusion using the proprietary protein NELL-1 in combination with demineralized bone matrix (DBM). The company went public on November 27, 2015, and employs two full-time staff.
Bone Biologics (BBLG) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Bone Biologics's actual EPS was -$1.33, missing the estimate of -$0.59 per share, resulting in a -124.81% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
